Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of diabetic nephropathy

George L Bakris, MD
Section Editors
Richard J Glassock, MD, MACP
David M Nathan, MD
Deputy Editor
John P Forman, MD, MSc


Diabetic nephropathy occurs in type 1 (formerly called insulin-dependent or juvenile onset) and type 2 (formerly called non-insulin-dependent or adult onset) diabetes mellitus, and in other secondary forms of diabetes mellitus, for example after pancreatitis or pancreatectomy, in which duration of diabetes is long-enough and level of glycemia high enough to result in complications. (See "Classification of diabetes mellitus and genetic diabetic syndromes".)

The following data concerning the epidemiology of renal disease may not represent the current clinical course of the disease. Some of the evidence was obtained before the availability of data supporting the efficacy of tight glycemic control, aggressive blood pressure and lipid control, and the specific benefit of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).

This topic provides an overview of diabetic nephropathy; treatment issues are discussed separately. (See "Treatment of diabetic nephropathy".)


Diabetic kidney disease is defined by characteristic structural and functional changes. The predominant structural changes include mesangial expansion, glomerular basement membrane thickening, and glomerular sclerosis. (See 'Pathology' below.)

The major clinical manifestations of diabetic nephropathy are albuminuria, less often hematuria, and, in many patients, progressive chronic kidney disease, which can be slowed or prevented with optimal therapy. (See "Treatment of diabetic nephropathy".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Oct 20, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. de Boer IH, Rue TC, Cleary PA, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011; 171:412.
  2. Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010; 77:57.
  3. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52:1036.
  4. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006; 29:1560.
  5. Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18:1353.
  6. Matsumura N, Hanatani M, Nishino T, et al. [The clinico-pathological significance of hematuria in diabetics]. Nihon Jinzo Gakkai Shi 1994; 36:1036.
  7. O'Neill WM Jr, Wallin JD, Walker PD. Hematuria and red cell casts in typical diabetic nephropathy. Am J Med 1983; 74:389.
  8. Lopes de Faria JB, Moura LA, Lopes de Faria SR, et al. Glomerular hematuria in diabetics. Clin Nephrol 1988; 30:117.
  9. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990; 39:1116.
  10. Newman DJ, Mattock MB, Dawnay AB, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9:iii.
  11. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 2014; 63:S3.
  12. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296:156.
  13. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55:1.
  14. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307.
  15. Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type I diabetes. Am J Med 1985; 78:785.
  16. Matsushima M, Tajima N, LaPorte RE, et al. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetes Epidemiology Research International (DERI) U.S.-Japan Mortality Study Group. Diabetologia 1995; 38:236.
  17. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996; 50:2041.
  18. Bojestig M, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330:15.
  19. Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294:1782.
  20. Rossing P, Rossing K, Jacobsen P, Parving HH. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995; 44:739.
  21. Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007; 50:721.
  22. de Boer IH, Afkarian M, Rue TC, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2014; 25:2342.
  23. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321:1074.
  24. Nelson RG, Knowler WC, Pettitt DJ, et al. Diabetic kidney disease in Pima Indians. Diabetes Care 1993; 16:335.
  25. Pavkov ME, Knowler WC, Bennett PH, et al. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int 2006; 70:1840.
  26. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341:1127.
  27. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27:167.
  28. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225.
  29. Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54:2983.
  30. Fioretto P, Steffes MW, Brown DM, Mauer SM. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 1992; 20:549.
  31. Adler S. Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int 2004; 66:2095.
  32. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21:556.
  33. Nasr SH, D'Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 2007; 18:2032.
  34. Westall GP, Binder J, Kotsimbos T, et al. Nodular glomerulosclerosis in cystic fibrosis mimics diabetic nephropathy. Nephron Clin Pract 2004; 96:c70.
  35. Souraty P, Nast CC, Mehrotra R, et al. Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nat Clin Pract Nephrol 2008; 4:639.
  36. Suneja M, Khan A, Katz DA, et al. Nodular glomerulosclerosis in a kidney transplant recipient who smokes. Am J Kidney Dis 2007; 50:830.
  37. Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16:1135.
  38. Hilgers KF, Veelken R. Type 2 diabetic nephropathy: never too early to treat? J Am Soc Nephrol 2005; 16:574.
  39. Nagai Y, Yao L, Kobori H, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703.
  40. Harris RD, Steffes MW, Bilous RW, et al. Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int 1991; 40:107.
  41. Heilig CW, Concepcion LA, Riser BL, et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96:1802.
  42. Mishra R, Emancipator SN, Kern T, Simonson MS. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 2005; 67:82.
  43. Vasylyeva TL, Chen X, Ferry RJ Jr. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm IGF Res 2005; 15:207.
  44. Lin CL, Wang JY, Huang YT, et al. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006; 17:2812.
  45. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325:836.
  46. Singh AK, Mo W, Dunea G, Arruda JA. Effect of glycated proteins on the matrix of glomerular epithelial cells. J Am Soc Nephrol 1998; 9:802.
  47. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352:213.
  48. Maxhimer JB, Somenek M, Rao G, et al. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 2005; 54:2172.
  49. van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70:2100.
  50. Wilson DM, Luetscher JA. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 1990; 323:1101.
  51. Daneman D, Crompton CH, Balfe JW, et al. Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int 1994; 46:1154.
  52. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69:1503.
  53. Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17:1950.
  54. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56:393.
  55. Hohenstein B, Hausknecht B, Boehmer K, et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69:1654.
  56. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12:993.
  57. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63:209.
  58. Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal--regulated kinase and protein kinase Cdelta activities in human mesangial cells. J Am Soc Nephrol 2004; 15:2032.
  59. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19:2505.
  60. Lassila M, Jandeleit-Dahm K, Seah KK, et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16:363.
  61. Gruden G, Setti G, Hayward A, et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005; 16:688.
  62. Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005; 16:1711.
  63. Zhang SX, Wang JJ, Lu K, et al. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 2006; 17:475.
  64. Pfab T, Thöne-Reineke C, Theilig F, et al. Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol 2006; 17:1082.
  65. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44:1139.
  66. Burns WC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17:2484.
  67. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19:433.
  68. Kelly KJ, Burford JL, Dominguez JH. Postischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy. Am J Physiol Renal Physiol 2009; 297:F923.
  69. Kelly KJ, Dominguez JH. Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy. Nephrol Dial Transplant 2010; 25:3204.
  70. Sung SH, Ziyadeh FN, Wang A, et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17:3093.
  71. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13:1349.
  72. Wang S, de Caestecker M, Kopp J, et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17:2504.
  73. Janssen B, Hohenadel D, Brinkkoetter P, et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005; 54:2320.
  74. Isaka Y, Akagi Y, Kaneda Y, et al. Gene therapy by transforming growth factor beta receptor-IgG Fc chimera blocked glomerular hypertrophy in diabetic nephropathy (abstract). J Am Soc Nephrol 1997; 8:639A.
  75. Sharma K, Eltayeb BO, McGowan TA, et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34:818.
  76. Benigni A, Zoja C, Corna D, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14:1816.
  77. Dai C, Yang J, Bastacky S, et al. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004; 15:2637.
  78. Benigni A, Gagliardini E, Tomasoni S, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65:2193.
  79. Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002; 45:1572.
  80. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52:1023.
  81. Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12:329.
  82. Fornoni A. Proteinuria, the podocyte, and insulin resistance. N Engl J Med 2010; 363:2068.
  83. Gurley SB, Coffman TM. An IRKO in the Podo: impaired insulin signaling in podocytes and the pathogenesis of diabetic nephropathy. Cell Metab 2010; 12:311.
  84. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 2014; 63:S39.
  85. Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 1990; 39:761.
  86. Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 2004; 44:792.
  87. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 1999; 55:1582.
  88. Trevisan R, Viberti G. Genetic factors in the development of diabetic nephropathy. J Lab Clin Med 1995; 126:342.
  89. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33:438.
  90. Satko SG, Langefeld CD, Daeihagh P, et al. Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy. Am J Kidney Dis 2002; 40:489.
  91. Jeffers BW, Estacio RO, Raynolds MV, Schrier RW. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 1997; 52:473.
  92. Yoshida H, Kuriyama S, Atsumi Y, et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996; 50:657.
  93. Kuramoto N, Iizuka T, Ito H, et al. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis 1999; 33:276.
  94. Kunz R, Bork JP, Fritsche L, et al. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9:1653.
  95. Boright AP, Paterson AD, Mirea L, et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 2005; 54:1238.
  96. Hadjadj S, Tarnow L, Forsblom C, et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 2007; 18:1284.
  97. Pettersson-Fernholm K, Fröjdö S, Fagerudd J, et al. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int 2006; 69:1880.
  98. Shah VO, Scavini M, Nikolic J, et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab 1998; 83:2886.
  99. Ma RC, Tam CH, Wang Y, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304:881.
  100. Mueller PW, Rogus JJ, Cleary PA, et al. Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 2006; 17:1782.
  101. Pavkov ME, Bennett PH, Knowler WC, et al. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006; 296:421.
  102. Svensson M, Nyström L, Schön S, Dahlquist G. Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study. Diabetes Care 2006; 29:538.
  103. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy--an 8-year prospective study. Kidney Int 1992; 41:822.
  104. Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:1626.
  105. Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992; 41:829.
  106. Nowack R, Raum E, Blum W, Ritz E. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis 1992; 20:342.
  107. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 1993; 3:1458.
  108. Earle K, Viberti GC. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int 1994; 45:434.
  109. Hayashi K, Epstein M, Loutzenhiser R, Forster H. Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992; 2:1578.
  110. Brancati FL, Whittle JC, Whelton PK, et al. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA 1992; 268:3079.
  111. Smith SR, Svetkey LP, Dennis VW. Racial differences in the incidence and progression of renal diseases. Kidney Int 1991; 40:815.
  112. Kohler KA, McClellan WM, Ziemer DC, et al. Risk factors for microalbuminuria in black americans with newly diagnosed type 2 diabetes. Am J Kidney Dis 2000; 36:903.
  113. Chaiken RL, Palmisano J, Norton ME, et al. Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Int 1995; 47:1697.
  114. Schmidt K, Pesce C, Liu Q, et al. Large glomerular size in Pima Indians: lack of change with diabetic nephropathy. J Am Soc Nephrol 1992; 3:229.
  115. Myers BD, Nelson RG, Williams GW, et al. Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset. J Clin Invest 1991; 88:524.
  116. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46:871.
  117. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17:1695.
  118. de Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18:235.
  119. Morales E, Valero MA, León M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319.
  120. Saiki A, Nagayama D, Ohhira M, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005; 29:1115.
  121. Ahmed SB, Hovind P, Parving HH, et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28:1988.
  122. Ng LL, Davies JE, Siczkowski M, et al. Abnormal Na+/H+ antiporter phenotype and turnover of immortalized lymphoblasts from type 1 diabetic patients with nephropathy. J Clin Invest 1994; 93:2750.
  123. Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994; 43:441.
  124. Parving HH, Gall MA, Skøtt P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41:758.
  125. Christensen PK, Larsen S, Horn T, et al. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 2000; 58:1719.
  126. Huang F, Yang Q, Chen L, et al. Renal pathological change in patients with type 2 diabetes is not always diabetic nephropathy: a report of 52 cases. Clin Nephrol 2007; 67:293.
  127. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289:3273.
  128. Schwartz MM, Lewis EJ, Leonard-Martin T, et al. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998; 13:2547.
  129. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40.
  130. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12.
  131. Kasinath BS, Mujais SK, Spargo BH, Katz AI. Nondiabetic renal disease in patients with diabetes mellitus. Am J Med 1983; 75:613.
  132. Furuta T, Seino J, Saito T, et al. Insulin deposits in membranous nephropathy associated with diabetes mellitus. Clin Nephrol 1992; 37:65.
  133. Gans RO, Ueda Y, Ito S, et al. The occurrence of IgA-nephropathy in patients with diabetes mellitus may not be coincidental: a report of five cases. Am J Kidney Dis 1992; 20:255.
  134. Padilla B, Weiss M, Kant KS. Henoch-Schönlein purpura in a patient with diabetic nephropathy: case report and a review of the literature. Am J Kidney Dis 1992; 20:191.
  135. Matsumae T, Fukusaki M, Sakata N, et al. Thin glomerular basement membrane in diabetic patients with urinary abnormalities. Clin Nephrol 1994; 42:221.
  136. Mak SK, Gwi E, Chan KW, et al. Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 1997; 12:2588.
  137. Olsen S. Identification of non-diabetic glomerular disease in renal biopsies from diabetics--a dilemma. Nephrol Dial Transplant 1999; 14:1846.
  138. Mazzucco G, Bertani T, Fortunato M, et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002; 39:713.
  139. Hill PA, Barit D, Toussaint N. ARF in 2 patients with long-standing type 2 diabetes mellitus. Am J Kidney Dis 2005; 45:429.
  140. Pham TT, Sim JJ, Kujubu DA, et al. Prevalence of nondiabetic renal disease in diabetic patients. Am J Nephrol 2007; 27:322.
  141. Nasr SH, D'Agati VD, Said SM, et al. Pauci-immune crescentic glomerulonephritis superimposed on diabetic glomerulosclerosis. Clin J Am Soc Nephrol 2008; 3:1282.
  142. Heine GH, Sester U, Girndt M, Köhler H. Acanthocytes in the urine: useful tool to differentiate diabetic nephropathy from glomerulonephritis? Diabetes Care 2004; 27:190.
  143. Sharma SG, Bomback AS, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8:1718.
  144. Salvatore SP, Reddi AS, Chandran CB, et al. Collapsing glomerulopathy superimposed on diabetic nephropathy: insights into etiology of an under-recognized, severe pattern of glomerular injury. Nephrol Dial Transplant 2014; 29:392.
  145. Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003; 14:1396.
  146. Chong YB, Keng TC, Tan LP, et al. Clinical predictors of non-diabetic renal disease and role of renal biopsy in diabetic patients with renal involvement: a single centre review. Ren Fail 2012; 34:323.
  147. Myers DI, Poole LJ, Imam K, et al. Renal artery stenosis by three-dimensional magnetic resonance angiography in type 2 diabetics with uncontrolled hypertension and chronic renal insufficiency: prevalence and effect on renal function. Am J Kidney Dis 2003; 41:351.